ALLYX THERAPEUTICS
Allyx Therapeutics is a clinical-stage biotechnology company that develops therapies designed to reverse neurodegeneration. Allyx Therapeutics' product is an orally bioavailable small molecule that acts as a silent allosteric modulator, enabling clinicians to get a drug that is capable of delivering a disease-modifying approach and preserve cognition in patients.
ALLYX THERAPEUTICS
Industry:
Biotechnology Health Care Life Science Medical
Founded:
2018-01-01
Address:
New Haven, New York, United States
Country:
United States
Website Url:
http://www.allyxthera.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
7.81 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Juventas Therapeutics
Juventas Therapeutics is a clinical-stage biotechnology company developing regenerative therapies to treat life threatening diseases.
Seismic Therapeutic
Seismic Therapeutic is a biotechnology company advancing machine learning for immunology drug development.
Current Advisors List
Current Employees Featured
Founder
Investors List
Life Science Angels
Life Science Angels investment in Venture Round - Allyx Therapeutics
Connecticut Innovations
Connecticut Innovations investment in Convertible Note - Allyx Therapeutics
Official Site Inspections
http://www.allyxthera.com
- Host name: 76.105.208.35.bc.googleusercontent.com
- IP address: 35.208.105.76
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Allyx Therapeutics"
About Us - AllyxThera
Paul Fonteyne, MBA. Co-Founder. Paul Fonteyne has spent 30+ years in the pharmaceutical industry, retiring at the end of 2018 as Chairman of Boehringer-Ingelheim USA, the US arm of Boehringer-Ingelheim, a private held research …See details»
AllyxThera
October 30, 2023. Allyx Therapeutics releases top-line Phase 1a data for ALX-001, demonstrating oral administration is safe and well-tolerated at all doses and achieves full brain receptor occupancy.See details»
Allyx Therapeutics - Crunchbase Company Profile & Funding
Contact Email [email protected] Allyx Therapeutics is a clinical-stage biotechnology company that develops therapies to reverse neurodegeneration. Allyx Therapeutics' product is an orally …See details»
Allyx Therapeutics - LinkedIn
Allyx Therapeutics is a clinical stage biotechnology company aiming to develop disease modifying therapies for Alzheimer's and Parkinson's disease by targeting the underlying cause of synapse ...See details»
Allyx Therapeutics Inc. - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Allyx Therapeutics Inc. of New Haven, CT. Get the latest business insights from Dun & Bradstreet.See details»
Contact - AllyxThera
Allyx Therapeutics, Inc. 555 Long Wharf Drive Floor 11 New Haven, CT 06511. [email protected]See details»
Allyx Therapeutics - BioCT
Email: [email protected] General Information: Founded in 2019, Allyx Therapeutics is a biotechnology company based in New Haven, CT, developing new therapies to protect synapses from destruction in Alzheimer’s disease …See details»
Allyx Therapeutics - Overview, News & Similar companies
Www.allyxthera.com. Revenue <$5 Million. Industry Business Services General Business Services . Recent News & Media. No recent news or media. Overview ; Org Chart ; Who is Allyx …See details»
Allyx Therapeutics Inc. - VentureRadar
Website: https://allyxthera.com/ Develops therapies targeting synapse loss in Alzheimer's patients by blocking proteins involved in the process, with lead program ALX ...See details»
Allyx Therapeutics, Inc. - Drug pipelines, Patents, Clinical ... - Patsnap
Explore Allyx Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 4 clinical trials, 8 news, and 1 literature, Disease Domain:Nervous System Diseases, Endocrinology and Metabolic Disease, Technology Platform:Small molecule drug, Drug:BMS-984923.See details»
Allyx Therapeutics Announces First Parkinson’s Disease ... - BioSpace
Sep 4, 2024 Learn more at allyxthera.com. About the Duke Clinical Research Institute. The DCRI, part of the Duke University School of Medicine, is the largest academic clinical research …See details»
Allyx Therapeutics Announces Expansion into Parkinson’s
Mar 5, 2024 Learn more at allyxthera.com. Contact. Media: Eliza Schleifstein 917.763.8106 [email protected]. Investors: Tim Siegert 203-691-6543 [email protected] ...See details»
Careers - AllyxThera
Allyx Therapeutics, Inc. 555 Long Wharf Drive Floor 11. New Haven, CT 06511. [email protected]See details»
Allyx Therapeutics Announces First Parkinson’s Disease
Sep 4, 2024 Learn more at allyxthera.com. About the Duke Clinical Research Institute The DCRI , part of the Duke University School of Medicine, is the largest academic clinical research …See details»
Our Science - AllyxThera
ALX-001 (previously BMS-984923) is a silent allosteric modulator of mGluR5, a first-in-class compound that selectively blocks the pathogenic activation of the receptor while preserving the …See details»
Allyx Therapeutics Announces First Alzheimer’s Disease
Jun 11, 2024 Learn more at allyxthera.com. Contact. Media: Eliza Schleifstein 917.763.8106 [email protected]. Investors: Tim Siegert 203-691-6543 [email protected]. TagsSee details»
Allyx Therapeutics Announces First Parkinson’s ... - Pipelinereview
Sep 4, 2024 Learn more at allyxthera.com. About the Duke Clinical Research Institute. The DCRI, part of the Duke University School of Medicine, is the largest academic clinical research …See details»
Allyx Therapeutics Lead Compound ALX-001 is Safe and
Oct 30, 2023 Its lead compound, ALX-001 is a first-in-class oral therapy with a unique mechanism of action at mGluR5 currently in clinical development in Alzheimer’s disease. …See details»
Allyx Therapeutics Announces Expansion into Parkinson’s Disease ...
Mar 5, 2024 Its lead compound, ALX-001, is a first-in-class oral therapy with a unique mechanism of action at mGluR5 in clinical development for Alzheimer’s disease and Parkinson’s disease. Learn more at allyxthera.com. Contact. Media: Eliza Schleifstein 917.763.8106 [email protected]. Investors: Tim Siegert 203-691-6543 [email protected]See details»
News and Events - AllyxThera
2024 Michael J. Fox Foundation Parkinson’s Disease Therapetuics Conference – October 17, 2024. Evaluating the Pre-clinical Efficacy of a mGluR5 Silent Allosteric Modulator, ALX-001 …See details»